Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension to its Series B financing round, which was originally led by HBM Partners in April 2013. All existing investors - aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, LSP - Life Sciences Partners, Roche Venture Fund, management, a trustee- pool of Curetis employees and private angel investors - participated in the extension financing, investing EUR 7.5 million on a pro rata basis. QIAGEN and LSP Health Economics Fund (LSP-HEF) are joining as new investors, committing a total of EUR 7 million.